#258 – AMA #48: Blood pressure—how to measure, manage, and treat high blood pressure
“If you care about your brain, if you care about your heart and if you care about your kidneys, you need low blood pressure. I think we can say that as confidently as we can say almost anything in medicine.” —Peter Attia
#255 ‒ Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease and CVD, familial hypercholesterolemia, and more | John Kastelein, M.D., Ph.D.
“One of the things that is so dangerous about this disorder is that the plaque that you get in FH is a soft plaque.” —John Kastelein
#252 ‒ Latest insights on Alzheimer’s disease, cancer, exercise, nutrition, and fasting | Rhonda Patrick, Ph.D.
“My perspective has shifted as any scientist that’s following data should… When new data comes out, you have to reassess things.” —Rhonda Patrick
A new analysis of REDUCE-IT: benefits of omega-3s vs. harm from placebos
A secondary analysis of biomarker data from REDUCE-IT raises questions about the apparent benefits of EPA-derivative icosapent ethyl
#247 ‒ Preventing cardiovascular disease: the latest in diagnostic imaging, blood pressure, metabolic health, and more | Ethan Weiss, M.D.
“If everybody got truly optimal medical therapy, if we didn’t have barriers to using all these tools in everybody, I think this disease would largely be controlled.” —Ethan Weiss
More hype than substance: erythritol and cardiovascular risk
A newly-published study caught public attention by reporting an association between the common sweetener erythritol and increased risk of heart attack and stroke, but there’s more to the story.
#240 ‒ The confusion around HDL and its link to cardiovascular disease | Dan Rader, M.D.
“HDL cholesterol itself is not directly and causally protective against atherosclerotic cardiovascular disease.” —Dan Rader
#238 – AMA #43: Understanding apoB, LDL-C, Lp(a), and insulin as risk factors for cardiovascular disease
“ApoB is a necessary, though not sufficient, factor in the development of ASCVD which means the more you lower it, the more you lower risk. Full stop.” —Peter Attia
#230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more | Erin Michos, M.D.
“How we live the first half of our lives really influences our freedom for morbidity and mortality the second half of our lives.” —Erin Michos
Reassuring new data on statin-induced Lp(a) elevation
Statin therapy is known to raise Lp(a) particle concentration in some patients, but how does this impact the overall effect of these medications on ASCVD risk?